Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is discussed as a potential treatment for hair loss, with excitement about its promise but skepticism about its current effectiveness. Users mention combining it with treatments like minoxidil, finasteride, and microneedling, but emphasize it is not a cure.

Homemade topical finasteride solutions are discussed, with one user using 30% ethanol, 50% propylene glycol, and 20% water. Alternatives like dissolving finasteride pills in minoxidil and using stemoxydine are also mentioned.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

A new hair loss treatment involving Keratin Microsphere Gel is discussed, with skepticism and jokes about its effectiveness and comparisons to other treatments. Users are doubtful and make light of the situation, referencing past disappointments and the study's focus on mice.

Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.

Switching from liquid to foam Minoxidil to avoid scalp irritation, with a method to melt the foam for easier application. Users discuss alternatives and personal experiences with Minoxidil, including issues with propylene glycol and different application methods.

GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

Minoxidil, dutasteride, and copper peptides are used in a tattooing method for hair regrowth, with some users noting better results compared to oral treatments. Copper peptides are considered to have minimal impact, but the method may reduce side effects.

P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

A naturally occurring sugar, 2-deoxy-D-ribose, in a hydrogel form, shows promise for hair regrowth similar to minoxidil in rats. The user plans to synthesize it for topical application, seeking input from others.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.

Everychem's solution, similar to PP405, has mixed results for hair regrowth, with some users reporting improvements and others seeing no change or worsening hair loss. Users are sharing experiences and updates to determine its effectiveness.

People are discussing the potential of a new hair loss treatment, pp405, and its approval timeline, comparing it to existing treatments like Minoxidil and finasteride. There is skepticism about its effectiveness and concerns about the time it will take for approval and availability, especially in Europe.

The user is experiencing scalp itching from a PG ethanol base in their hair loss treatment, which includes 0.025% finasteride and 2.5% minoxidil, and is seeking alternatives without PG or ethanol. Suggestions include Zeuss non-PG foam and Ulo, which do not use PG or hydrocortisone.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Sodium dodecyl sulfate, oleic acid, and palmitoleic acid may promote hair growth, but their safety and effectiveness for humans are uncertain. Users consider trying these treatments cautiously, exploring alternatives like ostrich oil and microneedling.

HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

A user has been taking finasteride for 7 months and is experiencing watery semen as the only side effect. They are considering taking zinc supplements to improve this condition.